Silence Therapeutics to Present at the Jefferies Healthcare Conference...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 4, 2023

Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid • Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs • CAMS Wins Ragan CSR, ESG and Diversity Awards • HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation' • NBLSA and Blueprint Prep Join Forces to Increase Diversity in the Legal Field • MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX • Dr. Toba N. Niazi Appointed Chief of the Section of Neurosurgery and Co-Director of Nicklaus Children's Brain Institute • Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception • Chicago Non-Profit Raises Joy through 1st Annual Double Good Days Event • BioTek reMEDys Calls for Heightened Communication Around Health Literacy Month • THE COMMUNITY SPIRIT VODKA JOINS FORCES WITH ONE GRAND BOOKS TO CELEBRATE LGBTQ+ HISTORY MONTH THROUGH LITERATURE • Enjoy Prime Big Deals from Jackery: Up to 40% OFF Fan Favorites From Oct. 1 Through Oct. 11, And $50,000 Worth of Giveaways • Riddle & Brantley Partners with Groundbreaking Nonprofit to Combat the Growing Mental Health Crisis Facing Today's Youth • Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers • Global Clean Energy Reports Largest Camelina Acreage Worldwide • Qwoted Launches Free Networking Tools for PR Industry • Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call • UCB presents late-breaking posters at Child Neurology Society Meeting • ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives • LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF URO BLADDER CONTROL

Silence Therapeutics to Present at the Jefferies Healthcare Conference

LONDON , May 31 /Businesswire/ - Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will present at the Jefferies Healthcare Conference on Wednesday, June 7^th at 4:00 – 4:25 PM EDT.

A live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.